Now in its third year, Pharma Sustainability Integrates brings together experts, leaders, academics and policy makers from across industry and healthcare to discuss the challenges and opportunities related to reducing the environmental impact of the industry and the wider healthcare system. Featuring keynote presentations, fireside chats and interactive debate-led panel sessions, the agenda will cover policy, strategy, innovation and how industry can play its part in reducing its own Carbon footprint and that of the wider healthcare eco-system.
This year we will discuss:
How are the sustainability policies and expectations of government, investors, customers and employees shaping the future of pharma?
How can innovative technology help to reduce the carbon footprint of the entire pharmaceutical supply chain, from manufacturing to patient delivery?
As a ‘scope 3’ source of Carbon for Healthcare systems, how can the sector partner to reduce the overall environmental impact of Healthcare?
AstraZeneca UK
Country President
Tom is President of AstraZeneca UK, the UK’s leading biopharmaceutical company. He became President in March 2020, following 20 years working in senior roles across Asia, Europe, and the US. Tom is passionate about making a difference to people’s lives through groundbreaking science and new medicines, through working in partnership to tackle pressing health challenges, and accelerating the UK as a global centre of excellence for life sciences. Prior to joining AZ, Tom spent a decade in consulting and venture capital, and a year in the British Army.
AstraZeneca
Senior Vice President, Business Development Operations
Shaun Grady is responsible for representing AstraZeneca’s whole enterprise across the UK. In this role, reporting to CEO Pascal Soriot, Shaun works closely with relevant senior leaders across AstraZeneca to champion and support our science and R&D function, operations and manufacturing, commercial business, and our corporate priorities across the life sciences ecosystem in the UK. Shaun also manages critical relationships with senior Government representatives, business leaders and industry associations, as well as leading on advocacy for key policy priorities. As UK Chair he also represents AstraZeneca’s global enterprise, where we support and leverage the UK’s unique diplomatic and economic networks to improve trade and international cooperation in life sciences. Additionally, Shaun chairs the UK Leadership Team, the UK Employee Forum and the UK Inclusion and Diversity working group. Before becoming the Chair of AstraZeneca UK, Shaun led the company’s business development function where he has worked for over 20 years, and before that was a member of the legal team working on corporate transactions. Shaun has played a central role in almost every major business development activity during his time with the company, including the merger of Astra and Zeneca, the acquisition of Cambridge Antibody Technology (CAT), and later MedImmune and Amylin, and the buy-out of Bristol-Myers’ Squibb’s interest in the AstraZeneca-BMS Diabetes Alliance. More recently, Shaun led the transaction team for AstraZeneca’s global ADC collaborations with Daichi Sankyo, and the acquisition of Gracell, Icosovax and Fusion, as well as the collaboration with Ecogene. Shaun is a Board member at the BioIndustry Association (BIA) and CBI President’s Committee, is Chairman of the Board of Directors of Cambridge United Football Club, and a Board member at Cambridge Arts Theatre, and at Prostate Cancer Research, as well as an Honorary Fellow at The University of Cambridge Judge Business School and Lucy Cavendish College Cambridge.
CPI, Medicines Manufacturing Innovation Centre
Managing Director, Pharma, Healthtech and Quality
Prior to joining CPI Dave worked for GSK. He joined the company in 1992 as a PhD Chemist from Glasgow University. He has over 20 years’ experience at GSK carrying out a number of Technical, Compliance and Manufacturing leadership roles. In 1997 he moved to Irvine to take up a lead chemist role before coming Quality Control Manager in 1998. He joined the site leadership team in 2001 to run Technical Development before moving to manufacturing as Actives Production Director in 2005.
During this time he completed a Masters degree in Manufacturing Leadership at Cambridge University. In 2007 he moved to GSK House to work on a central network re-structuring project before becoming Site Director at Montrose in October 2008. At Montrose, he led the transformation of the site to manufacture over 12 products for GSK including a major investment programme. In 2011 he was appointed VP Primary Supply Chain with responsibility for global Active Pharmaceutical Ingredients (API) manufacture and supply, a network of GMS sites across the world including facilities in Asia and Europe. In 2017 he was appointed VP Head of GMS Strategy with responsibility for manufacturing strategy, deployment of strategic programmes, performance management and advocacy.
He plays an active role with a number of Governments and is currently co-chair of the Life Sciences Scotland Industry Leadership Group.
Honeywell & CiPPPA
Global Sustainability Lead, Chairman
Duncan leads the vision and execution of Honeywell’s sustainability goals around Aclar, Solstice Air, and healthcare packaging.
He has worked for 15 years in the pharmaceutical packaging industry and in recent years, has delivered unique sustainability solutions to the UK market, helping to advance circularity around difficult-to-recycle healthcare packaging materials.
He is a founding alumnus of the Sustainable Medicines Partnership and a founder and Chairman of the Circularity in Primary Pharmaceutical Packaging Accelerator (CiPPPA), a not-for-profit, pre-competitive action collaborative focused on the alignment of sustainable activities within the pharmaceutical industry, enabling the reduction, collection, and recycling of pharmaceutical packaging associated with blister packs, metered dose inhalers and auto injectors.
Bayer
Head of Sustainability & Public Affairs UK & Ireland
Andy spent 17 years in senior Sales leadership and Commercial roles within FMCG, Skincare and Pharma, he then made a career pivot over 3 years ago to proactively supercharge and lead the Sustainability agenda at Bayer UK & Ireland. Andy works across the full spectrum of Sustainability, covering Policy, ESG & Non-Financial Disclosures, Carbon Footprinting, Impact Valuation, Life Cycle Assessments, Employee Engagement and many more.
Andy voices how driving a culture of sustainability and incorporating it into everyday roles and responsibilities is essential to delivering a net zero agenda as well as the powerful role story telling plays in supporting organisations transformation from Board level all the way through the business.
How can you accurately assess the effectiveness of your sustainability initiatives and what does the customer really want? This session will explore the metrics and methodologies used by companies, providing insights on accurately tracking and reporting environmental impact and what they mean for stakeholders.
Revolutionize the future of medicine with eco-innovative design, paving the way to a zero-carbon footprint. Join us to lead the charge in sustainable pharmaceutical breakthroughs.
Medicines Manufacturing Innovation Centre, CPI
Director
John is the Director of the Medicines Manufacturing Innovation Centre, Glasgow, a collaboration between CPI, University of Strathclyde, UK Research & Industry, Scottish Enterprise and founding industry partners, AstraZeneca and GSK.
The center’s principle goal is to accelerate the adoption of innovative technology and techniques in pharmaceutical manufacturing, with a mission to make the next generation of medicines available, affordable and without impacting the planet. MMICs strategic focus is on oligonucleotides, continuous manufacturing, digital and date.
Prior to joining CPI in October 2019 John worked for GSK, joining the company in 1986 as a Process Chemist at the Worthing Site. During his time on Site he held roles covering all aspects of the manufacturing supply chain from large scale fermentation, fine chemicals (both chemical and enzymatic conversions), Chemical Development and Secondary Sterile Operations.
After 10 years of site base roles he was seconded to Head office to lead a workstream of a global supply restructuring programme. In 2000 he moved to the Irvine plant to lead the Development team and take change of the construction a new 300te nanomilling and spray drying plant. This period was followed with a number of roles working out of GSK House in strategic program leadership including Head of the Global Manufacturing & Supply Programme Management Office, 5 years in the Core Business Services Function (IT, Procurement and Real estate) as Head of PMO and finally back to manufacturing to Leader a Global manufacturing restructuring programme.
John has a BSc (Hons) in Chemistry, an MBA from Strathclyde University Business School, a Private Pilot’s license and double decker bus license.
How can sustainability training be embedded into company culture, guiding suppliers and teams toward sustainable solutions? What actions are promoting diversity and inclusion in pharma to ensure its future? How does the sustainability agenda attract early career talent, and in what ways are apprenticeships contributing to tackling sustainability challenges?
AstraZeneca UK
HR Director
Phoebe is the HR Director for AstraZeneca UK, where she champions sustainable practices in people management and organisational development. With an innate curiosity and creativity, Phoebe is dedicated to fostering an inclusive and sustainable workplace culture. She has over 15 years of experience leading People & Organisation agendas, working in the US, Netherlands, Italy, and the UK across various industries, which has equipped her with a global perspective on sustainable business practices.
Phoebe holds an undergraduate degree in Poetry from Colorado College and a Masters in Public Administration from Cornell University. She resides in Cambridge with her husband and three children. In her personal time, she enjoys traveling, cooking, running, cycling, gardening, and reading.
Medicines Manufacturing Innovation Centre, CPI
Head of Sustainability (Pharma),
Deborah joined the Medicines Manufacturing Innovation Centre, part of CPI, in 2022. She is currently the Head of Sustainability (Pharma), leading CPI’s Pharma sustainability initiatives, having held a previous role at CPI as a Grand Challenge lead, responsible for the advancement of technological innovation around continuous manufacturing within the centre.
With ~ 20 years’ experience in the pharmaceutical industry (Q-One BIOTECH Ltd, Piramal Pharma, Bioreliance, Merck), she has held various roles. From QA to Development Scientist, advancing to Head of Research and Development for a CRO/CMO specialising in Antibody Drug Conjugates. She has also held commercial roles, both within Business development and leading the Strategic Program Management team to ensure successful partnerships. Deborah has extensive CMC experience from proof-of-concept development to commercialising drug products, leading large skilled teams.
Deborah graduated with a BSc (Hons) in Biochemistry and Molecular Biology as well as a PhD in Glycobiology, both from the University of Strathclyde, Glasgow.
Sustainable Healthcare Coalition
Chair
As a leading expert in sustainability and health, I currently serve as Chair of the Sustainable Healthcare Coalition a pioneering organisation that brings together partners to advance sustainable healthcare.
Additionally, I act as an independent expert advisor and board member for various national and global organisations, providing valuable insight and guidance on well-being and sustainability.
I’m passionate about reframing thinking and have a track record of developing innovative strategies and programmes at the heart of business and government.
My background includes senior roles in the UK Government as Deputy Chief Medical Officer and Director General, in the World Health Organisation as Director of Chronic Disease and Health Promotion, and in the private sector, as Bupa’s Chief Wellbeing Officer and as a Director in PwC’s health and sustainability teams.
I am a visiting Professor at UCL and a Senior Associate at Cambridge Institute for Sustainability Leadership and have served on various boards including British Land’s Sustainability Advisory Panel, Marks and Spencer’s Sustainable Retail Advisory Board, and Business in the Community’s Wellbeing Leadership Team.
There is a fine balance between genuine sustainability efforts and greenwashing. Can new “green laws” help celebrate real progress while ensuring companies back their sustainability claims with solid data? Join us to discuss sustainability practises in industry.
UCL & Real Zero
Professor Intensive Care Medicine & Co-founder
Intensive Care clinician. Director UCL Centre for Human Health and Performance, with >550 papers (8 in Nature, inc first description of a ‘gene for human performance’.)
Extensive work in Climate Change. Founder https://realzero.earth/
Consults in medtech (inc previously for Google Health/ Deepmind) and pharma (lately vaccines).
Board, Silver Creek Ltd
ex-Board Chair ed-tech: Obrizum https://www.obrizum.com/
5 charity boards
22 years leader in health and climate change (chair 27-country Lancet Countdown)
Founder and Board, ‘Real Zero Ltd’ (non-profit action on climate change)
Award winning author (2 x childrens’ books, 1 x thriller) and script editor.
Public speaker (>600 invited lectures to public, business, medicine and science) fronting >6 TV shows, inc 5 Royal Institution Xmas Lectures 2007)- https://londonspeakerbureau.com/speaker-profile/hugh-montgomery/
CMS CAMERON MCKENNA NABARRO OLSWANG LLP
UK Head of Advertising and Marketing, Of Counsel (IP Team)
Stuart Helmer is Of Counsel in the Intellectual Property team and head of the CMS London advertising and marketing group. He has over 15 years’ experience of advising a wide range of businesses on advertising and marketing compliance and disputes and is individually ranked for Advertising and Marketing by Chambers. Clients describe him as ”bloody fantastic … really, really pragmatic and an absolute lifesaver”.
Stuart frequently advises on comparative advertising disputes, including in major High Court litigation in relation to allegedly misleading comparative advertising. He also frequently advises on making and responding to complaints to the Advertising Standards Authority, where he has particular experience of late-stage interventions to reverse or mitigate a draft decision against his client. He also has extensive experience of implementing and operating day-to-day advertising clearance programmes.
The Discovery Centre (DISC)
A state-of-the-art global R&D facility located in the heart of the Cambridge Biomedical Campus.
Cambridge, one of the most exciting bioscience hotspots in the world, is home to the largest UK research and development centre – The DISC. Here more than 2,300 scientists work in drug discovery and development, across our therapy areas, each playing a central role in our mission to deliver life-changing medicines to patients. The DISC is uniquely designed to strengthen collaboration, promote openness, and improve the sustainability of every aspect of our science and our business operations.
The DISC is a 12 – minute bus ride from Cambridge Railway Station.
Biomedical Campus, 1 Francis Crick Ave, Trumpington, Cambridge CB2 0AA
